<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Proposed diagnostic features of asthma and COPD overlap</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Proposed diagnostic features of asthma and COPD overlap</h1>
<div class="graphic"><div class="figure"><div class="ttl">Proposed diagnostic features of asthma and COPD overlap</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Study</td> <td class="subtitle1">Major criteria</td> <td class="subtitle1">Minor criteria</td> <td class="subtitle1">Diagnosis</td> </tr> <tr class="divider_bottom"> <td>Gibson, 2009<sup>[1]</sup></td> <td> <ul> <li>Clinical symptoms of chronic airway disease, FEV<sub>1</sub>/FVC &lt;70% </li> <li>FEV<sub>1</sub> &lt;80% </li> <li>Bronchial hyper-responsiveness defined as a PD15 &lt;12 mL (provocative dose of hypertonic saline that induces a 15% fall in FEV<sub>1</sub>) </li> </ul> </td> <td> </td> <td>3 major criteria</td> </tr> <tr class="divider_bottom"> <td>Soler-Cataluna, 2011<sup>[2]</sup></td> <td>COPD plus: <ul class="decimal_heading"> <li>Positive bronchodilator test defined by increase in FEV<sub>1</sub> ≥15% and ≥400 mL </li> <li>Sputum eosinophilia </li> <li>History of asthma </li> </ul> </td> <td>COPD plus: <ul class="decimal_heading"> <li>High total serum IgE </li> <li>Personal history of atopy </li> <li>Positive bronchodilator test, ie, increase in FEV<sub>1</sub> ≥12% and ≥200 mL over baseline on ≥2 occasions </li> </ul> </td> <td> <p>2 major criteria</p> <p><strong>OR</strong></p> <p>1 major criteria</p> <p><strong>AND</strong></p> 2 minor criteria</td> </tr> <tr class="divider_bottom"> <td>Koblizek, 2013<sup>[3]</sup></td> <td>COPD plus: <ul class="decimal_heading"> <li>Positive bronchodilator test defined by increase in FEV<sub>1</sub> &gt;15% and &gt;400 mL </li> <li>Methacholine challenge test positivity </li> <li>FE<sub>NO</sub> ≥45 to 50 ppb and/or sputum eosinophils &gt;3% </li> <li>History of asthma </li> </ul> </td> <td>COPD plus: <ul class="decimal_heading"> <li>Mildly positive bronchodilator test, ie, increase in FEV<sub>1</sub> &gt;12% and &gt;200 mL </li> <li>Elevated IgE </li> <li>History of atopy </li> </ul> </td> <td> <p>2 major criteria</p> <p><strong>OR</strong></p> <p>1 major criteria</p> <p><strong>AND</strong></p> 2 minor criteria</td> </tr> <tr class="divider_bottom"> <td>GINA/GOLD Criteria, 2015<sup>[4]</sup></td> <td>More likely COPD if: <ul class="decimal_heading"> <li>Onset age &gt;40 years </li> <li>Persistence of symptoms </li> <li>Daily symptoms with exertional dyspnea and good/bad days </li> <li>Chronic cough and sputum precede onset of dyspnea, unrelated to triggers </li> <li>Documented persistent airflow limitation (post-bronchodilator FEV<sub>1</sub>/FVC &lt;70%) </li> <li>Lung function abnormal between symptoms </li> <li>Previous doctor diagnosis of COPD, chronic bronchitis or emphysema </li> <li>Heavy exposure to a risk factor (tobacco smoke, biomass fuel) </li> <li>Symptoms slowly worsening over time (progressive course over years) </li> <li>Rapid-acting bronchodilator treatment provides only limited relief </li> <li>Chest radiograph with features of severe hyperinflation </li> </ul> </td> <td>More likely asthma if: <ul class="decimal_heading"> <li>Onset age &lt;20 years </li> <li>Variation in symptoms within short periods </li> <li>Worsening of symptoms at night/early morning </li> <li>Symptoms triggered by exercise, emotions/laughter, dust, or exposure to allergens </li> <li>Documented airflow limitation variability (peak flow, spirometry) </li> <li>Lung function normal between symptoms </li> <li>Prior doctor diagnosis of asthma </li> <li>Family history of asthma or atopy/eczema </li> <li>No worsening of symptoms over time (symptoms vary either seasonally or from year to year) </li> <li>May improve spontaneously or have an immediate response to bronchodilators or to inhaled steroids over weeks </li> <li>Chest radiograph normal </li> </ul> </td> <td> <p>If ≥3 items are present for either asthma or COPD, the patient is likely to have that disease</p> A similar number of items for asthma and COPD is suggestive for ACO</td> </tr> <tr class="divider_bottom"> <td>Cosio, 2016<sup>[5]</sup></td> <td>COPD plus: <ul class="decimal_heading"> <li>History of asthma </li> <li>Bronchodilator response to salbutamol &gt;15% and 400 mL </li> </ul> </td> <td>COPD plus: <ul class="decimal_heading"> <li>IgE &gt;100 IU </li> <li>History of atopy </li> <li>Two separated bronchodilator responses to salbutamol &gt;12% and 200 mL </li> <li>Blood eosinophils &gt;5% </li> </ul> </td> <td> <p>1 major criteria</p> <p><strong>OR</strong></p> 2 minor criteria</td> </tr> <tr class="divider_bottom"> <td>Sin, 2016<sup>[6]</sup></td> <td>COPD plus: <ul class="decimal_heading"> <li>FEV<sub>1</sub>/FVC &lt;0.7 or LLN in patients ≥40 years of age </li> <li>≥10 pack years of tobacco smoking <strong>OR</strong> equivalent indoor or outdoor air pollution exposure </li> <li>Documented history of asthma before 40 years of age <strong>OR</strong> bronchodilator reversibility &gt;400 mL in FEV<sub>1</sub> </li> </ul> </td> <td>COPD plus: <ul class="decimal_heading"> <li>Documented history of atopy or allergic rhinitis </li> <li>Bronchodilator reversibility of FEV<sub>1</sub> ≥200 mL and 12% from baseline on ≥2 visits </li> <li>Peripheral blood eosinophil count of ≥300 cells/mL </li> </ul> </td> <td> <p>3 major criteria</p> <p><strong>AND</strong></p> 1 minor criteria</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Cataldo, 2017<sup>[7]</sup></td> <td>ACO in a COPD patient: <ul class="decimal_heading"> <li>High degree of variability in airway obstruction over time: FEV<sub>1</sub> variation ≥400 mL </li> <li>High degree of response to bronchodilators: &gt;200 mL and 12% above baseline </li> </ul> </td> <td>ACO in a COPD patient: <ul class="decimal_heading"> <li>Personal or family history of atopy and/or IgE sensitivity to one or more airborne allergens </li> <li>Elevated blood or sputum eosinophils or increased FE<sub>NO</sub> </li> <li>Asthma diagnosed before the age of 40 </li> <li>Symptom variability </li> <li>Age (in favor of asthma) </li> </ul> </td> <td class="divider_bottom" rowspan="2"> <p>2 major criteria</p> <p><strong>AND</strong></p> 1 minor criteria</td> </tr> <tr class="divider_bottom"> <td>ACO in an asthma patient: <ul class="decimal_heading"> <li>Persistence over time of airflow obstruction (FEV<sub>1</sub>/FVC &lt;0.7 or &lt;LLN) </li> <li>Exposure to noxious particles or gases, with ≥10 pack years for smokers </li> </ul> </td> <td>ACO in an asthma patient: <ul class="decimal_heading"> <li>Lack of response on acute bronchodilator tests </li> <li>Reduced lung diffusion capacity </li> <li>Little variability in airway obstruction </li> <li>Age in favor of COPD (&gt;40 years) </li> <li>Presence of emphysema on chest CT scan </li> </ul> </td> </tr> <tr> <td>Miravittles, 2017<sup>[8]</sup></td> <td> <ul> <li>Age &gt;35 years </li> <li>Postbronchodilator FEV<sub>1</sub>/FVC &lt;70% </li> <li>≥10 pack years tobacco smoke </li> </ul> </td> <td> <ul> <li>Current diagnosis of asthma </li> <li>No current diagnosis of asthma but a bronchodilator response to albuterol ≥15% and 400 mL and/or blood eosinophils ≥300 cells/microL </li> </ul> </td> <td> <p>3 major criteria</p> <p><strong>AND</strong></p> 1 minor criteria</td> </tr> </tbody></table></div><div class="graphic_footnotes">FEV<sub>1</sub>: forced expiratory volume in one second; FVC: forced vital capacity; PD15: provocative dose; COPD: chronic obstructive pulmonary disease; IgE: immunoglobulin E; FE<sub>NO</sub>: fraction of exhaled nitric oxide; ppb: parts per billion; ACO: asthma COPD overlap; IU: international units; LLN: lower limit of normal.</div><div class="graphic_reference">References:

	<ol>
<li>Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax 2009; 64:728.</li>
<li>Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012; 48:331.</li>
<li>Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013; 157:189.</li>
<li><a href="https://goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf" target="_blank">goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf</a> (Accessed on October 16, 2019).</li>
<li>Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest 2016; 149:45.</li>
<li>Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J 2016; 48:664.</li>
<li>Cataldo D, Corhay JL, Derom E, et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2017; 12:601.</li>
<li>Miravitlles M, Alvarez-Gutierrez FJ, Calle M, et al. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J 2017; 49.</li>
</ol></div><div id="graphicVersion">Graphic 126333 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
